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Background: Identification of differentially expressed genes from transcriptomic studies is one of the most
common mechanisms to identify tumor biomarkers. This approach however is not well suited to identify interaction
between genes whose protein products potentially influence each other, which limits its power to identify
molecular wiring of tumour cells dictating response to a drug. Due to the fact that signal transduction pathways
are not linear and highly interlinked, the biological response they drive may be better described by the relative
amount of their components and their functional relationships than by their individual, absolute expression.
Results: Gene expression microarray data for 109 tumor cell lines with known sensitivity to the death ligand cytokine
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was used to identify genes with potential functional
relationships determining responsiveness to TRAIL-induced apoptosis. The machine learning technique Random Forest
in the statistical environment “R” with backward elimination was used to identify the key predictors of TRAIL sensitivity
and differentially expressed genes were identified using the software GeneSpring. Gene co-regulation and statistical
interaction was assessed with q-order partial correlation analysis and non-rejection rate. Biological (functional) interactions
amongst the co-acting genes were studied with Ingenuity network analysis. Prediction accuracy was assessed by calculating
the area under the receiver operator curve using an independent dataset. We show that the gene panel identified could
predict TRAIL-sensitivity with a very high degree of sensitivity and specificity (AUC = 0 · 84). The genes in the panel are
co-regulated and at least 40% of them functionally interact in signal transduction pathways that regulate cell death and
cell survival, cellular differentiation and morphogenesis. Importantly, only 12% of the TRAIL-predictor genes were
differentially expressed highlighting the importance of functional interactions in predicting the biological response.
Conclusions: The advantage of co-acting gene clusters is that this analysis does not depend on differential expression
and is able to incorporate direct- and indirect gene interactions as well as tissue- and cell-specific characteristics. This
approach (1) identified a descriptor of TRAIL sensitivity which performs significantly better as a predictor of TRAIL
sensitivity than any previously reported gene signatures, (2) identified potential novel regulators of TRAIL-responsiveness
and (3) provided a systematic view highlighting fundamental differences between the molecular wiring of sensitive and
resistant cell types.
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Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL, TNFSF10), a member of the TNF cytokine fam-
ily, is an emerging therapeutic option for various can-
cers. Due to the tumor-specific cytotoxicity of TRAIL,
its recombinant version and agonistic antibodies against
the death-inducing TRAIL receptors (TNFRSF10A/DR4,
TNFRSF10B/DR5) are currently being tested in Phase I/
II clinical trials. The basis for the tumor-specific action
of TRAIL is that during malignant transformation cells
become sensitive to TRAIL [1]. During later progression
however, tumors can re-acquire resistance to evade
immune-mediated killing and thus, prediction of tumor
TRAIL-responsiveness is critical [2]. While TRAIL can
be a very potent tumoricidal agent due to its ability to
target both the tumor cells and the tumor vasculature
[3], administration of TRAIL to resistant tumors may
trigger invasiveness and promote metastasis [4-6] further
highlighting the need for robust biomarkers predicting
TRAIL-responsiveness. While the TRAIL-induced apop-
totic machinery is well studied and a number of regula-
tory mechanisms have been identified, none of them
have proven to be useful as a predictive marker.
Owing to its high sensitivity and full coverage of the hu-
man genome, transcriptomics is one of the most widely
applied tools for biomarker research by selecting genes
that are differentially expressed in the majority of the sam-
ples, or in a specific subgroup. This gene-by-gene ap-
proach however cannot address the question of how
genes relate to each other in determining the biological
outcome. Often the change in the expression of key regu-
latory genes is minor, or it is only significant in a small
subset within a diverse sample cohort, or its effect on the
phenotype is conditional on the expression level of other
genes. Thus the relative expression of genes acting/partici-
pating in the same biological process and their combina-
torial analysis may better describe the behavior of a cell
and predict the response to a stimulus.
Here we show that it is possible to predict TRAIL sensi-
tivity with high accuracy by using hierarchical decision
tree analysis of transcriptomic data. We found that the
identified predictor genes are not differentially expressed,
but instead they have linked biological functions (includ-
ing inhibition, activation, induction of expression etc.).
We report here that these “co-acting” gene clusters can be
identified from transcriptomic data and these co-acting
genes could predict TRAIL-responsiveness with a much
higher degree of sensitivity and specificity (AUC= 0.84)
than the currently available best-performing gene signa-
ture predicting TRAIL-responsiveness (AUC of 0.72) [7].
Results
The focus of the study was to identify genes that predict
TRAIL-responsiveness and analyse their correlation andfunctional interactions, such as regulation by direct inter-
action, post-translational modification, induction or repres-
sion of expression, induction of degradation etc. (analysis
workflow is shown in Additional file 1: Figure S1).
First, each gene was mapped to a singular “best” probe-
set using the JetSet algorithm as described in the Materials
and methods [8]. Expression values of the selected 19,190
probesets were used to identify genes that predict TRAIL-
sensitivity by growing decision tree ensembles in the Ran-
dom Jungle implementation of the Random Forest (RF)
algorithm [9,10]. The algorithm generates a large num-
ber of independent decision trees each containing a
random subset of the samples and a random subset of
the predictors (genes). Each decision tree branches
downward by repeated selection of genes that best sep-
arate the samples, until the sample subset is fully di-
vided into homogeneous groups (sensitive or resistant)
as shown in Figure 1. Random forests are not limited
by the need of a gene to be differential expressed but
can include gene interactions, as the gene used to parti-
tion the data at a node can be influenced by the genes
at higher levels of the tree. We refer to the group of
such genes as co-acting.
The importance of the 19,190 genes in predicting
TRAIL-responsiveness was determined by calculating the
mean decrease in Gini-importance, which is based on cal-
culating the reduction in prediction accuracy after permut-
ing the expression value of the gene in question (referred
to as Gini-importance). From the Gini-importance list the
top fifth percentile (the highest ranking 1000 genes) was
retained for further analysis (Figure 2A). These genes could
predict TRAIL-responsiveness with an out of bag (OOB)
error of 16%. To improve the performance of the model,
the bottom-ranking genes of the Gini-importance list were
stepwise removed (backward elimination), the RF model
rerun and the performance assessed by calculating the
OOB error (Figure 2B). This analysis identified that the top
350 as well as the smaller subset of the top-ranking 120
genes, performed best with OOB error rates of 10 · 1% and
8 · 3%, respectively. Since the contribution and importance
of individual genes is likely to be different in different sam-
ple types, the larger, 350 gene subset was chosen as the
TRAIL-response predictor co-acting gene panel (listed in
Additional file 2: Table S1).
An independent dataset (NIH CellMiner) was used to
determine the prediction accuracy of the 350 gene-panel
and it confirmed that these genes predicted TRAIL-
responsiveness with high accuracy of 0.84, measured as
the area under the receiver operator characteristic curve
(AUC of ROC curve, Figure 2C). To test the relevance
of these genes as predictors of TRAIL-responsiveness,
the sensitivity value (sensitive or resistant) of the cell
lines was changed to the incorrect alternative in a ran-







































Figure 1 Depiction of a classification tree. For a tree within the random forest a bootstrap or subset of cell lines (samples) and genes
(variables) is randomly selected. The gene from this random subset whose expression best divides the cell lines as cleanly as possible into
sensitive and resistant is then selected. In the example above this gene was DCTN6. The two groupings or daughter nodes are not pure, they
have some resistant and some sensitive cell lines, so a new subset of genes is selected and the gene which best divides the cell lines is selected;
in the example above these genes were EMID1 and CLVS1. This recursive partitioning continues until terminal nodes (TN; green colored nodes)
are reached, these being groupings in which only sensitive or resistant cell lines are found. In this manner classification trees consider the
expression of one gene in relation to another (“co-acting genes”) in determining the biological response (i.e. TRAIL-sensitivity).
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05) confirming that the prediction accuracy achieved
was unlikely to have occurred by chance (Figure 2C).
The genes differentially expressed between sensitive and
resistant cell lines were then identified and compared to
the co-acting gene panel identified with RF. There were
254 genes that showed a minimum of 2-fold difference in
expression and were considered statistically significant.
Interestingly, the majority (82%) of the co-acting genes
were not differentially expressed (Figure 2D).
In order to assess whether the genes selected with RF
are co-regulated q-order partial correlation with non-
rejection rate (NRR) thresholding was carried out. The
analysis showed strong correlation amongst the genes;
even at a stringent non-rejection rate threshold of 0 · 15
(at q = 35) over 90% of the genes had at least one inter-
acting gene partner (Table 1). The most significant co-
regulated gene clusters were identified by graphing the
co-regulated gene network from these associations at de-
creasing NRR threshold until individual gene clusters
separated out (q = 35, NRR = 0 · 075, Figure 3).
Finally, biological functional network analysis was car-
ried out to determine whether the protein products of
the co-regulated genes interact in vivo, within the cell.
Multiple databases of experimentally proven biological
interactions (such as induction, binding, activation, in-
hibition as well acting within the same canonical signal-
ing pathway) were searched using the Ingenuity Pathway
Analysis Platform (Ingenuity, IPA, Qiagen). The analysisshowed that the 350 genes are enriched in several highly
interconnected canonical signal transduction pathways,
which were focused around 5 major themes: 1. Cell cycle
and DNA damage, 2. Nuclear receptor signaling, 3.
Neurotransmitter metabolism/signaling 4. Inflammatory/
immune reaction and 5. Cancer tissue-specific pathway
transformation (Figure 4).
Analysis of biological interactions showed that over
40% of the genes (141 in total) were proven or predicted
components of three interconnected signaling networks
controlling (1) cell death and pro-survival signal trans-
duction (65 genes, Figure 5), (2) cellular differentiation
and morphogenesis (45 genes, Additional file 3: Figure
S2), and (3) cancer related signaling pathways (31 genes,
Additional file 4: Figure S3). The remaining genes could
not be grouped into signaling networks based on the
current literature about them in the searched databases.
These networks confirm that interactions between the
350 genes exist at the biological level. Notably, in the
network of cell death and pro-survival signaling path-
ways, the majority of the 350 genes are upstream regula-
tors of protein kinases and transcription factors, such as
NF-κB (nuclear factor-kappa B), PI3K (phosphatidylinositol
3-kinase), JNK (c-Jun N-terminal kinase), and ERK (extra-
cellular signal-regulated kinase) (Figure 5).
By contrast, in the cancer-related and the cell differenti-
ation and morphogenesis networks the TRAIL-predictor
genes are mostly target genes, rather than upstream regu-










































































































































































Figure 2 Identification of the core co-acting gene set. (A) Gene ranking by Gini-importance. A singular “best” probeset for each gene was
used to grow 10,000 classification trees. The importance of each gene in classifying cell lines as sensitive or resistant to TRAIL was measured by
mean decrease in Gini-importance in the training dataset. The probesets above the red line represent the top 5th percentile retained for further
analysis. Only genes with Gini-importance value higher than zero were plotted. (B) The top 350 genes predict TRAIL-responsiveness with high
accuracy. From the top-ranked 1000 genes, the lowest ranked genes were stepwise removed (by units of 100 and then 10) and the performance
of the remaining gene-set was determined by calculating the out of bag classification error (OOB) (stepwise 10-gene unit removal between top
300-top 200 genes had no effect and thus it is not shown on the graph). (C) Validation of the prediction accuracy of the 350 co-acting genes.
The area under the receiver operator curve (AUC) was calculated as a measure of the models specificity and sensitivity in the independent test
dataset on the dataset (black line, AUC = 0 · 85) as well as after swapping the sensitivity values of a randomly-selected 50% of the cells lines (red
line, AUC = 0 · 48). The graph shows the AUC. This is a representative graph from 100 repeats of random permutations. (D) The 350 co-acting
genes are not identified by differential expression analysis. A histogram displaying the gene distribution based on fold difference in expression
between TRAIL sensitive and resistant cell lines. The number of genes from the panel of 350 co-acting genes falling in the individual fold
difference ranges on the histogram is indicated by the numbers above each column.
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The main examples include nuclear protein 1 (NUPR1,
a binding partner for p53 and the estrogen receptor
with a multifaceted role in tumorigenesis), p53, the
DNA helicase SMARCA4 (alters chromatin structure
for transcription activation), lysine-specific demethylase
5B (KDM5B), estrogen receptor, heat shock factor-1
(HSF-1, transcription factor for stress-mediated heat
shock protein induction), and bromodomain-containing
protein 4 (BRD4, chromatin reader protein) (Additional
file 3: Figure S2 and Additional file 4: Figure S3).
The components and regulators of TRAIL signal
transduction are considered to be well studied and
understood. We identified the 26 core effectors of
TRAIL-mediated apoptosis signaling from the literature(Figure 6A) and determined whether the inter-
relationships between these genes using the RF model
would predict TRAIL-sensitivity. We found that the pre-
diction accuracy of the 26 core effectors was inferior
compared to the 350 co-acting gene set (AUC = 0 · 74)
and backward elimination by mean decrease in Gini-
importance only worsened the prediction suggesting that
genes not in this core set are likely to be important for
predicting TRAIL-responsiveness (Figure 6B).
Discussion
Biomarkers are pillars of diagnostic biology both for de-
tection and prognosis. In the last number of years there
has been a paradigm shift from the identification of
prognostic and diagnostic biomarkers to biomarkers that
Table 1 The percentage of genes which had at least one
co-regulated gene partner
Q value
NRR 1 35 70
1 100 100 100
0.8 100 100 100
0.6 100 100 99
0.4 100 100 57
0.2 100 97 26
0.15 100 93 19
0.1 100 81 13
0.05 100 59 9
0.01 100 33 5
0.005 100 28 5
The percentage of genes which had at least one co-regulated gene partner
within the 350 co-acting gene panel determined by q-order partial correlation
at different non-rejection rate thresholds.
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facilitated by the advent of high-throughput technologies
such as genome-wide association analysis, transcripto-
mics or metabolomics and already resulted theranostic
diagnostics, such as the Oncotype-DX biomarker panel
for treatment-identification for breast cancer patients
[11]. Differential gene expression patterns from tran-
scriptome studies can be also used to identify drugs that
have the potential to reverse an unfavorable phenotype,Figure 3 Co-regulated gene clusters. Relationship between gene pairs w
non-rejection rate threshold of 0.075 at q = 35 were graphed using qpgrap
components of cell death and cell survival signal transduction pathways de
embryonic development network shown in Additional file 2: Figure S2 and
system network depicted in Additional file 3 Figure S3.such as drug-resistance with the help of the computa-
tional algorithm Connectivity mapping (Broad Institute
of Massachusetts Institute of Technology, Harvard
University) [12].
Biomarkers to predict the functionality of the TRAIL
apoptotic pathway in cancer cells are becoming increas-
ingly important with emerging promising phase I trials
and new pre-clinical studies showing the potency of
TRAIL on the tumor vasculature and synergistic DR5-
activation by the combination of TRAIL and agonistic
DR5 antibody (AMG655, Amgen) in ovarian cancer
[3,13]. Some of the pathway regulators have been indi-
cated as potential biomarkers, including GalNT14,
c-FLIP, DcR1 or DcR2 as individual markers [14-19] or
groups of differentially expressed genes [7]. Currently
the best classifier of TRAIL sensitivity is a 71-gene sig-
nature of genes differentially expressed between TRAIL-
resistant and sensitive tumor cell lines with a prediction
accuracy of AUC = 0 · 72 [7].
Here we show that by using machine-learning
methods we could predict the TRAIL-responsiveness of
cancer cell types with an accuracy superior to any of the
current markers. Importantly, most of the identified
genes were not differentially expressed; instead 40% of
them were linked based on their biological function.
The advantage of the co-acting gene clusters in predic-
tion can be due to their ability to capture the non-linear
nature of signal transduction pathways, which one-FS
as assessed using q-order partial correlation and gene clusters passing
h package in R. Green coloured gene nodes represent identified
picted in Figure 5, blue nodes of components of the cellular- and
pink nodes showing genes within the cancer-related and reproductive
IL-15 Production
IL-12 Signalling and Production in MØ
VDR/RXR Activation
Polyamine Regulation in Colon Cancer




Aryl Hydrocarbon Receptor Signalling
HIF1a Signalling
Chronic Myeloid Leukaemia Signalling
Renal Cell Carcinoma Signalling
Cyclinsand Cell Cycle Regulation
GADD45 Signalling
DNA damage induced 14-3-3 Signalling
P53 Signalling
DNA DSB Repair by Homologous Recombination
Cell Cycle G1/S Checkpoint Regulation
Nicotine Degradation II
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Acetone Degradation 1(To Methylglyoxal)
Nicotine Degradation III
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Thyroid Hormone Metabolism (Conjugation and/or Degradation)
Figure 4 The Canonical pathways the 350 co-acting genes are involved in. The canonical signal transduction pathways and their interactions
that the 350 co-acting genes function within. The intensity of the box colour is indicative of statistical significance as determined by Fishers exact test.
DSB: double strand break, EC: endothelial cell, GADD45: growth arrest and DNA damage-inducible 45, IL: interleukin, MØ: macrophage, NF-kB: nuclear
factor kappa B, RXR: retinoid X receptor, TR: thyroid receptor, VDR: vitamin D receptor.
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poorly reflect. It is also well established that not all cells
utilize the same mechanism to block apoptosis [1,19].Ensembles of decision tree models can follow and iden-
tify branching gene interactions and are able to simul-
taneously test a number of potential routes of co-acting
Figure 5 The genes determining TRAIL-response-tend to be upstream regulators of components of cell death and cell survival signal
transduction pathways. The figure shows direct (solid lines) and indirect interactions (dashed lines) amongst components of the cell death and
survival signal transduction pathways. Genes from the 350 gene panel are coloured grey. Lines with arrowheads indicate functional interaction,
such as regulation of expression or activity, while lines without arrowheads indicate protein-protein interactions.
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highly diverse sample sets. Finally, unlike differential ex-
pression analyses, co-acting gene clusters do not exclude
genes which are differentially expressed only in a small
subset of a diverse sample population.
In comparison, the well-documented components of
the TRAIL pathway were poor predictors (AUC= 0.74).
Complementing this, out of the 350 co-acting genes only
six, namely DR4, DR5, DcR2, osteoprotegerin, Caspase-8,
and heme-oxidized IRP2 ubiquitin ligase 1 (HOIL1)
are well characterized components of TRAIL signaling
(Additional file 2: Table S2). Another 14 genes linked to
TRAIL-sensitivity by at least one study are present in the
panel, including mixed-lineage kinase domain-like(MLKL), DNA-binding death effector domain-containing
protein 2 (DEDD2), NADPH oxidase organizer 1, the
serine/threonine kinase Ataxia telangiectasia mutated
(ATM), polypeptide N-acetylgalactosaminyltransferase-14
and cyclin-dependent kinase 2 (please refer to Additional
file 2: Table S2 for full list). The remaining 336 genes have
not been associated with TRAIL. These genes may be co-
regulated with other genes that regulate TRAIL sensitivity,
but have no effect on the pathway (bystanders), although
it is more likely that many of them directly or indirectly
regulate TRAIL-sensitivity.
IPA functional pathway analysis revealed that 40% of
the identified genes have already been reported to inter-





































































Figure 6 The known core components and regulators of the TRAIL apoptotic machinery do not predict TRAIL sensitivity with a high
degree of sensitivity and specificity. (A) The selected 26 core component genes and regulators of the TRAIL apoptotic. (B) Performance of the
26 “TRAIL effectors” as a classifier assessed using the same approach as for the whole transcriptome (workflow shown in Additional file 1: Figure
S1). The 26 core effectors predicted TRAIL sensitivity poorly (AUC = 0.46). Removal of any of the core effectors caused a decrease in the model’s
ability to predict sensitivity to TRAIL.
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of the TRAIL signaling machinery, such as NF-κB, p53,
or AKT. In addition to these known TRAIL-signaling regu-
lators, other nodal points in the signaling networks were
proteins that have established roles in cancer progression
and/or resistance to cytotoxic drugs but have not been im-
plicated in TRAIL-induced apoptosis previously. For ex-
ample KDM5B (Histone demethylase JARID1B) is
overexpressed in many cancers including breast, prostate,
and lung cancer as well as melanoma where it confers resist-
ance to apoptotic stimuli such as cisplatin and vemurafenib
[20,21]. Recent reports suggest that KDM5B functions
through E2F1/2, which is known to be able to modulate sen-
sitivity to TRAIL [22,23]. Another example is NUPR1 (Nu-
clear protein 1), known to be highly expressed in a wide
range of cancerous malignancies and its expression has been
inversely correlated with the induction of apoptosis by vari-
ous compounds such as doxorubicin [24,25].
Conclusions
We show that a random forest classifier based on gene ex-
pression performs significantly better than previously re-
ported biomarkers in predicting sensitivity to TRAIL in
tumor cell lines perhaps because it allows a more flexible de-
scription of the molecular networks present in individual
cells or cell types. These findings shed light on why previous
studies failed to find a reliable marker of TRAIL sensitivity
and also pinpoint potential novel regulators of the pathway.
Materials and methods
Analysis of microarray data
Raw transcriptome microarray data for 109 cell lines
from Gene Expression Omnibus (GEO) accession num-
ber GSE8332 (training dataset) [26] and for an additional40 tumor cell lines (NIH CellMiner, test dataset) was
acquired in CEL file format. Background correction and
normalization of the datasets has been performed using
the RMA algorithm in the Affy package of Bioconductor
[27] in the statistical environment, R (version 2.10.1).
Noise in the analysis caused by multiple probesets per
gene was reduced by identifying the probeset best rep-
resenting each gene based on scoring and ranking the
probesets for specificity, splice isoform coverage and
robustness against degeneration using the JetSet algo-
rithm [8].
Differentially expressed genes were identified using
Genespring GX v11. After importing the CEL files, gene
expression values were transformed (Log2) and normal-
ized to the 75th percentile using the RMA algorithm. For
each cell line the genes whose expression was above the
expression value of the 20th percentile across all cell
lines were selected. These genes were filtered by retain-
ing only those which were present in at least 75% of the
cell lines and/or exhibited a greater than 2 fold change
in expression between TRAIL sensitive and resistant cell
lines. One-way ANOVA unequal variance (Welch) was
used to test for significance using a cut-off value of
p ≤ 0.05. Multiple testing corrections were done by
Benjamini-Hochberg.Determining TRAIL sensitivity of cancer cell lines
TRAIL sensitivity of the cell lines was assessed and de-
scribed by Wagner and colleagues using MTT assay [26].
A cell line was defined as being sensitive if 1 ug/ml re-
combinant human TRAIL (rhTRAIL) reduced viability
to 50% within 72 h or less and resistant if the reduction
in viability was less than 50%.
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Jetset-identified mRNA probesets for each gene were ex-
tracted from the training microarray data and were used
for classifying the cell line samples into TRAIL-sensitive
and resistant groups using random jungle, a parallel imple-
mentation of random forest (RF) modeling reducing com-
putational time for high dimensional datasets (number of
classification trees = 10,000, mtry = default). In order to
avoid imbalance between the number of sensitive and re-
sistant cell lines during training, the sample number to
grow the trees was set to 30 sensitive and 30 resistant cell
lines and the remaining samples were used to determine
the OOB error rate (sampsize). The genes were ranked by
mean decrease in Gini-importance. In order to determine
the core co-acting gene-set, the lowest ranking genes were
iteratively removed and the model’s performance tested by
determining out of bag (OOB) error rate. Performance of
the final model was measured by predicting TRAIL-
responsiveness of the test dataset and calculating the area
under the receiver operator curve (AUC) from 10 repeats.
All statistical analyses were carried out using Random Jun-
gle [9] and RandomForest [10] packages in the R (version
3 · 0 · 3) environment (http://www.r-project.org/).
Gene relationship analysis
The strength of the statistical interactions between genes
was measured with q-order partial correlation using the
qpgraph package in the Bioconductor project in R (ver-
sion 3 · 0 · 3) [28]. This analysis determines interaction
between two genes while filtering out potential effects of
other genes (number of genes for filtering is the q value).
Non-rejection rates were calculated from the normalized
gene expression data using q values ranging between 1–
105 q-order partial correlations. Gene regulatory net-
works where nodes represent genes and edges represent
the partial correlation between the genes were graphed
using the igraph package in R (version 3 · 0 · 3).
Ingenuity pathway analysis (IPA)
Biological interactions and inter-relationship amongst the
co-acting genes were analyzed using the Ingenuity IPA net-
work analysis tool (Qiagen) by performing core analysis
with the following settings: reference set: human genome
U133 plus 2 · 0 Array, included both direct and indirect re-
lationships experimentally observed limited to human with
the maximum number of network components set to 140
genes. Statistical significance for canonical pathway and
network analysis was determined by Fisher’s exact test.Additional files
Additional file 1: Figure S1. Workflow of gene expression analysis.Additional file 2: Table S1. Genes of the 350 co-acting gene classifier
panel. Bold highlighted genes are known components or regulators of
TRAIL-sensitivity. Table S2. Genes of the 350 co-acting gene panel with
known association with TRAIL sensitivity.
Additional file 3: Figure S2. TRAIL-predictor genes interact in
cancer-related signal transduction networks.
Additional file 4: Figure S3. TRAIL-predictor gene product are
interacting proteins of cellular differentiation and morphogenesis
regulatory pathways.
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